NCT04435197View on ClinicalTrials.gov

Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Pembrolizumab Injection

Pre-operative Pembrolizumab+chemoradiotherapy

Trial Locations (2)

200025

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai

All Listed Sponsors
collaborator

Fujian Medical University Union Hospital

OTHER

collaborator

Zhejiang University

OTHER

collaborator

The First Affiliated Hospital of Anhui Medical University

OTHER

collaborator

The First Affiliated Hospital of Nanchang University

OTHER

lead

Ruijin Hospital

OTHER

NCT04435197 - Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter